Lord, Abbett & Co
RLAY icon

Lord, Abbett & Co’s Relay Therapeutics RLAY Stock Holding History

Lord, Abbett & Co’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.68M Buy
+410,723
New +$5.96M 0.02% 422
2020
Q4 		– Sell
-227,392
Closed -$9.69M – 693
2020
Q3 		$9.69M Buy
+227,392
New +$8.67M 0.03% 478

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Lord, Abbett & Co's RLAY Position: Q2 2026 in Review

Lord, Abbett & Co opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 410,723 shares worth $7.68M. The stake represents 0.02% of the portfolio and ranks #422 among its holdings. This is a return to the name: Lord, Abbett & Co previously reported a position in RLAY as recently as Q3 2020.

Lord, Abbett & Co first reported a position in RLAY in Q3 2020 and has held it in 2 quarters since. The position peaked at $9.69M in Q3 2020. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Lord, Abbett & Co held 410,723 shares of Relay Therapeutics worth $7.68M as of Q2 2026.
  • Relay Therapeutics was a new Lord, Abbett & Co position in Q2 2026.
  • Relay Therapeutics made up 0.02% of Lord, Abbett & Co's portfolio in Q2 2026, its #422 holding.
  • Lord, Abbett & Co first reported a position in Relay Therapeutics in Q3 2020 and has held it in 2 quarters since.
  • Lord, Abbett & Co's Relay Therapeutics position peaked at $9.69M in Q3 2020.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.